Literature DB >> 19878385

Patients with hypertension and the cardiometabolic syndrome: the potential impact of inflammatory biomarkers.

Alanna Morris1, Keith C Ferdinand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19878385      PMCID： PMC8673403          DOI： 10.1111/j.1751-7176.2009.00189.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  16 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  C-reactive protein (CRP)-lowering agents.

Authors:  Kailash Prasad
Journal:  Cardiovasc Drug Rev       Date:  2006

3.  Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.

Authors:  Paul M Ridker; Eleanor Danielson; Nader Rifai; Robert J Glynn
Journal:  Hypertension       Date:  2006-05-19       Impact factor: 10.190

4.  Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.

Authors:  Keith C Ferdinand; Luther T Clark; Karol E Watson; Ryan C Neal; Clinton D Brown; B Waine Kong; Boisey O Barnes; William R Cox; Franklin J Zieve; Jonathan Isaacsohn; Joseph Ycas; Philip T Sager; Alex Gold
Journal:  Am J Cardiol       Date:  2005-11-28       Impact factor: 2.778

5.  Use of statins and blood pressure.

Authors:  Dana E King; Arch G Mainous; Brent M Egan; Marty Player; Mark E Geesey
Journal:  Am J Hypertens       Date:  2007-09       Impact factor: 2.689

6.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

7.  C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study).

Authors:  Michelle A Albert; Robert J Glynn; Julie Buring; Paul M Ridker
Journal:  Am J Cardiol       Date:  2004-05-15       Impact factor: 2.778

8.  Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.

Authors:  Bernhard Schieffer; Christoph Bünte; Jana Witte; Kirsten Hoeper; Rainer H Böger; Edzard Schwedhelm; Helmut Drexler
Journal:  J Am Coll Cardiol       Date:  2004-07-21       Impact factor: 24.094

9.  C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.

Authors:  Paul M Ridker; Julie E Buring; Nancy R Cook; Nader Rifai
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

10.  The effect of extended-release metoprolol succinate on C-reactive protein levels in persons with hypertension.

Authors:  Dana E King; Brent M Egan; Arch G Mainous; Mark E Geesey
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-04       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.